Iktos

Executive Summary

Iktos is a French biotechnology company specializing in AI-driven small-molecule drug discovery. Founded in 2016, the company combines generative AI, retrosynthesis planning, and robotic automation to compress the traditional drug discovery timeline from several years to under 24 months. Its platform integrates molecular design, synthesis prediction, and automated lab workflows, enabling faster identification of preclinical candidates. By partnering with pharmaceutical and biotech firms, Iktos generates revenue through collaborations while also building an internal pipeline. The company's end-to-end approach addresses key bottlenecks in early-stage drug development, such as hit identification and lead optimization, leveraging proprietary AI models and a growing dataset. With a presence in Paris and strategic partnerships, Iktos is positioned as a key player in the AI-drug discovery space, though it faces competition from established firms like Recursion and Exscientia. The company's ability to scale its platform and secure large deals will be critical for long-term success.

Upcoming Catalysts (preview)

• Q3 2026Major pharmaceutical partnership announcement70% success
• Q4 2026Preclinical data readout for internal pipeline candidate50% success
• H2 2026Series C funding round60% success